EA200500873A1 - Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита - Google Patents

Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита

Info

Publication number
EA200500873A1
EA200500873A1 EA200500873A EA200500873A EA200500873A1 EA 200500873 A1 EA200500873 A1 EA 200500873A1 EA 200500873 A EA200500873 A EA 200500873A EA 200500873 A EA200500873 A EA 200500873A EA 200500873 A1 EA200500873 A1 EA 200500873A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sequences
hiv
expression
rna
double
Prior art date
Application number
EA200500873A
Other languages
English (en)
Other versions
EA009290B1 (ru
Inventor
Живен Жу
Юся Фень
Коньлин Зуо
Юеюань Ли
Original Assignee
Бейджинг Джоинн Фармасьютикал Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бейджинг Джоинн Фармасьютикал Сентер filed Critical Бейджинг Джоинн Фармасьютикал Сентер
Publication of EA200500873A1 publication Critical patent/EA200500873A1/ru
Publication of EA009290B1 publication Critical patent/EA009290B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение предусматривает набор анти-ВИЧ-нуклеотидов и способ их применения для лечения и профилактики СПИД. Последовательности нуклеотидов представлены в виде таблицы последовательностей. Изобретение превосходит известные технологии благодаря следующим характеристикам: высоко консервативные последовательности рибонуклеиновой кислоты получают методом сравнения всех опубликованных последовательностей генома ВИЧ. Двухцепочечные последовательности РНК, полученные из последовательностей, эффективно ингибируют экспрессию генов ВИЧ. Экспрессию генов ВИЧ также ингибируют посредством двухцепочечной шпилькообразной РНК, транскрибированной в клетках, трансфицированых рекомбинантыми плазмидами, которые содержат ДНК последовательности, кодирующие РНК последовательности. Кроме того, экспрессию генов ВИЧ подавляют в клетке с транскрибированной двухцепочечной РНК, соответствующей последовательностям РНК, кодируемым рекомбинантным аденовирус-ассоциированным вирусом.
EA200500873A 2002-12-18 2003-12-16 Набор анти-вич-олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита EA009290B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB021567859A CN1301263C (zh) 2002-12-18 2002-12-18 一组抗hiv感染及防治艾滋病的核苷酸序列及其应用
PCT/CN2003/001068 WO2004055035A1 (fr) 2002-12-18 2003-12-16 Groupe de fragments d'acide nucleique s'utilisant pour prevenir l'infection par vih ou le sida et utilisation correspondante

Publications (2)

Publication Number Publication Date
EA200500873A1 true EA200500873A1 (ru) 2006-08-25
EA009290B1 EA009290B1 (ru) 2007-12-28

Family

ID=32514455

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500873A EA009290B1 (ru) 2002-12-18 2003-12-16 Набор анти-вич-олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита

Country Status (12)

Country Link
US (5) US7906641B2 (ru)
EP (5) EP2246357B1 (ru)
JP (4) JP2006516122A (ru)
CN (1) CN1301263C (ru)
AP (1) AP2388A (ru)
AU (1) AU2003292852A1 (ru)
CA (5) CA2808584C (ru)
EA (1) EA009290B1 (ru)
ES (5) ES2394723T3 (ru)
HK (4) HK1150055A1 (ru)
OA (1) OA13148A (ru)
WO (1) WO2004055035A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100395334C (zh) * 2004-08-24 2008-06-18 暨南大学 抑制bcl-2基因表达的siRNA双链
CN1948475B (zh) * 2004-10-13 2010-12-08 厦门大学 可用于治疗艾滋病的重组表达载体、经改造的造血干细胞和方法
CN103316356B (zh) 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
US20170298357A1 (en) * 2014-08-28 2017-10-19 Chantelle Lisa Evelyn AHLENSTIEL Treatment of HIV
CN114081950B (zh) * 2020-08-24 2023-07-28 深圳市诺瑞博泰生物科技有限公司 Crem/icer基因或其转录体作为靶点在制备抗hiv药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US595768A (en) * 1897-12-21 And clarence ran
CA2685262A1 (fr) * 1989-06-02 1990-12-13 Institut National De La Sante Et De La Recherche Medicale Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
WO1993023574A1 (en) * 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
WO1995004818A1 (en) * 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
AU702266B2 (en) * 1995-08-25 1999-02-18 Regents Of The University Of California, The Chimeric antiviral agents which incorporate Rev binding nucleic acids
US6071743A (en) * 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU8160298A (en) * 1997-06-23 1999-01-04 Emory University Human immunodeficiency viruses causing aids in a nonhuman primate
EP1007657B1 (en) 1997-08-19 2006-02-08 Idera Pharmaceuticals, Inc. Hiv-specific oligonucleotides and methods of their use
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP3351773B2 (ja) * 1999-06-15 2002-12-03 学校法人慶應義塾 Ｈｉｖ−１のサブタイプ決定法
US7098030B2 (en) * 1999-12-31 2006-08-29 Mirus Bio Corporation Polyampholytes for delivering polyions to a cell
US6506596B2 (en) * 2000-06-01 2003-01-14 Anna-Lena Spetz-Holmgren Method of DNA transfer
ES2215494T5 (es) * 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Moléculas de RNA pequeñas que median la interferencia de RNA
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
ATE530657T1 (de) * 2001-12-19 2011-11-15 David Gladstone Inst Verfahren zur herstellung von zellinien mit latentem immunschwächevirus
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference

Also Published As

Publication number Publication date
US8263761B2 (en) 2012-09-11
HK1150055A1 (en) 2011-10-28
HK1150449A1 (en) 2011-12-30
HK1151029A1 (en) 2012-01-20
EP2246358B1 (en) 2012-07-25
CA2808318A1 (en) 2004-07-01
CA2808318C (en) 2015-04-28
EP2243786B1 (en) 2012-08-22
ES2395334T3 (es) 2013-02-12
CA2808592A1 (en) 2004-07-01
AP2005003344A0 (en) 2005-06-30
EA009290B1 (ru) 2007-12-28
EP2266995B1 (en) 2012-09-19
EP1584623B1 (en) 2012-08-22
AU2003292852A1 (en) 2004-07-09
WO2004055035A1 (fr) 2004-07-01
US8383804B2 (en) 2013-02-26
JP2006516122A (ja) 2006-06-22
JP2011036250A (ja) 2011-02-24
AP2388A (en) 2012-03-27
US8779113B2 (en) 2014-07-15
JP2011015692A (ja) 2011-01-27
EP2266995A1 (en) 2010-12-29
US8283462B2 (en) 2012-10-09
US20110117188A1 (en) 2011-05-19
HK1151294A1 (en) 2012-01-27
JP2011016822A (ja) 2011-01-27
OA13148A (en) 2006-12-13
CA2808592C (en) 2015-04-28
CN1301263C (zh) 2007-02-21
CA2808584C (en) 2015-04-14
US20110217361A1 (en) 2011-09-08
EP2243786A1 (en) 2010-10-27
US20060217326A1 (en) 2006-09-28
CA2808584A1 (en) 2004-07-01
CN1508141A (zh) 2004-06-30
CA2509827A1 (en) 2004-07-01
ES2394723T3 (es) 2013-02-05
ES2394270T3 (es) 2013-01-30
CA2509827C (en) 2013-05-14
EP1584623A4 (en) 2007-11-28
EP2246357A1 (en) 2010-11-03
EP2246357B1 (en) 2012-08-29
EP1584623A1 (en) 2005-10-12
US20110189264A1 (en) 2011-08-04
US20110217362A1 (en) 2011-09-08
CA2808190C (en) 2015-09-15
EP2246358A1 (en) 2010-11-03
ES2393870T3 (es) 2012-12-28
US7906641B2 (en) 2011-03-15
ES2396371T3 (es) 2013-02-21
CA2808190A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
US20170088828A1 (en) Compositions and methods for treatment of latent viral infections
RU2013111850A (ru) ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА А (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
JP2798305B2 (ja) アンチセンスオリゴヌクレオチドおよびヒト免疫不全ウイルス感染におけるその使用
DE602004030583D1 (de) Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen
WO2003023015A3 (en) Method for expression of small antiviral rna molecules within a cell
WO2007042899B1 (en) Human microrna targets in hiv genome and a method of identification thereof
JP2012136542A5 (ru)
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
RU2013124422A (ru) Лечение hbv-инфекции
WO2010060967A3 (en) Compositions and methods for treating retrovirus infections
WO2004047764A3 (en) Modulation of hiv replication by rna interference
US9198927B2 (en) Targeting opposite strand replication intermediates of single-stranded viruses by RNAI
EA200500873A1 (ru) Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита
EA200500879A1 (ru) Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati коровьей оспы
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
Damier et al. The D1-A2 and D2-A2 Pairs of Splice Sites from Human Immunodeficiency Virus Type 1 Are Highly Efficientin Vitro, in Spite of an Unusual Branch Site
Inouye et al. Two independent retrons with highly diverse reverse transcriptases in Myxococcus xanthus.
JP2006523103A5 (ru)
US9212363B2 (en) RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
Khrustalev Mutational pressure makes HIV1 gp120 linear B-cell epitopes shorter and may lead to their disappearance
WO2020223118A1 (en) Multiplex shrna for use in vectors
Ivashchenko et al. BIOINFORMATIC APPROACHES IN STUDY OF MIRNA INTERACTION WITH THE GENOMES OF THE SARS-COV-2, MERS-COV, AND SARS-COV
WO2023205657A2 (en) Compositions for restoring mecp2 gene function and methods of use thereof
Seo et al. Protection against lethal vaccinia virus infection in mice using an siRNA targeting the A5R gene
Şimşek Some Interesting Features of a Halobacterial Gene and its mRNA

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment